Comment on: “Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years”-Reference-Cited by-同舟云学术

Comment on: “Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years”

Published:2015-09-24 Issue:5 Volume:34 Page:763-764
ISSN:0724-4983
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

von Klot Christoph-A.,Merseburger Axel S.

Publisher

Springer Science and Business Media LLC

Subject

Urology

Link

http://link.springer.com/content/pdf/10.1007/s00345-015-1683-4.pdf

Reference5 articles.

1. Bensalah K, Roupret M, Xylinas E, Shariat S (2013) The survival benefit of lymph node dissection at the time of removal of kidney, prostate and urothelial carcinomas: what is the evidence? World J Urol 31(6):1369–1376. doi: 10.1007/s00345-013-1064-9

2. Seiler R, Studer UE, Tschan K, Bader P, Burkhard FC (2014) Removal of limited nodal disease in patients undergoing radical prostatectomy: long-term results confirm a chance for cure. J Urol 191(5):1280–1285. doi: 10.1016/j.juro.2013.11.029

3. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, Holland-Letz T, Hadaschik BA, Giesel FL, Debus J, Haberkorn U (2014) Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 41(1):11–20. doi: 10.1007/s00259-013-2525-5

4. Salvage treatment or active clinical surveillance for oligometastatic prostate cancer: a randomized phase II trial. University Hospital, Ghent, Belgium. ClinicalTrials.gov Identifier: NCT01558427. www.clinicaltrials.gov

5. Boorjian SA, Thompson RH, Tollefson MK, Rangel LJ, Bergstralh EJ, Blute ML, Karnes RJ (2011) Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol 59(6):893–899. doi: 10.1016/j.eururo.2011.02.026